Immuron Limited Q3 Sales reach 150% of 1HFY23 Sales

Immuron Limited (ASX: IMC) has announced Q3 FY23 sales statistics for its gastrointestinal and digestive health immune supplements Travelan® and Protectyn®. Travelan® and Protectyn® global Q3 YTD sales climbed by 239% in FY23 to AU$1.46 million, compared to AU$430 k at the same time in FY22. Travelan® and Protectyn® sales in Australia for Q3 were AU$577 k, a 101% increase over 1HFY23 sales (AU$287 k).

Australian Travelan® and Protectyn® Q3 YTD FY23 sales totalled AU$864 k, a considerable increase over the same time in FY22 (AU$80 k). Travelan® sales are increasing as international travel recovers. Short-term Australian resident departures in January 2023 were 80% of those in January 2019. Immuron continues to restock wholesalers in line with increasing pharmacy sales.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com